Company Medtide Inc.

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:09 2026-10-23 EDT			5-day change	1st Jan Change
19.38 ^HKD	+0.16%		-5.00%	-36.42%

09-24	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
09-24	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI

Business description: Medtide Inc.

Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Number of employees: 596

Sales by Activity: Medtide Inc.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Medical Labs & Research	282M	351M	337M	442M	570M

See all business segments

Geographical breakdown of sales: Medtide Inc.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
United States of America	99.55M	132M	115M	243M	331M
Europe	42.72M	45.02M	62.59M	48.62M	86.14M
Mainland China	85M	101M	74.12M	94.58M	78.97M
Japan	22.06M	55.16M	73.57M	31.19M	37.55M
Others	32.8M	16.93M	11.69M	24.64M	36.62M

See all geographic segments

Executive Committee: Medtide Inc.

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	2020-06-10
Li Jun Ding DFI	Director of Finance/CFO	50	2026-07-30
Wei Qun Xu DFI	Director of Finance/CFO	53	2020-09-30
Tao Cheng PRN	Corporate Officer/Principal	54	2024-05-13
Ching Chan SEC	Corporate Secretary	46	2026-07-30

See MEDTIDE INC. governance

Composition of the Board of Directors: Medtide Inc.

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	2020-06-10
Xiang Li Li BRD	Director/Board Member	51	2022-01-26
Xiang Li BRD	Director/Board Member	63	2022-01-26
Tao Cheng BRD	Director/Board Member	54	2024-05-13
Yi Hui Wu BRD	Director/Board Member	53	2022-01-26
Cheung Hoi Yu BRD	Director/Board Member	71	2024-05-22
Xun Zhu BRD	Director/Board Member	68	2024-05-22
Xin Sheng Xia BRD	Director/Board Member	41	2024-05-22

Composition of the Board of Directors

Shareholders: Medtide Inc.

Name	Stocks	%	Valuation
Qi Xu 42.01 %	59,567,875	42.01 %	163 M $
Xiang Li Li 25.36 %	35,957,000	25.36 %	99 M $
Li Xie 6.694 %	9,492,375	6.694 %	26 M $
Lanxi Puhuashuo Yangxiaxing Venture Capital Partnership LP 6.44 %	9,131,875	6.44 %	25 M $
Quzhou Haibang Peptide Venture Capital Partnership Ltd. Par 5.084 %	7,209,375	5.084 %	20 M $

List of MEDTIDE INC. shareholders

Company details: Medtide Inc.

Taide Pharmaceutical (Zhejiang) Co., Ltd.

69, 12 Street

310018, Hangzhou

http://www.medtideinc.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+0.16%	-5.00%	-36.67%	-	350M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	+0.26%	+1.67%	+40.89%	+157.55%	38.35B
Weighted average by Cap.	+0.39%	+2.72%	+47.49%	+158.58%